68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
4 citations
,
June 2025 in “MedComm” PROTACs show promise for cancer treatment, but designing them effectively is challenging.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
January 2016 in “AACE Clinical Case Reports” Treatment restored normal sexual characteristics and blood condition in a patient with testicular cancer.
May 2024 in “News Digital Object Group” 1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.
February 2014 in “Plastic and Reconstructive Surgery” The document doesn't provide a clear conclusion or detailed findings about the impact of certain cells on cancer treatment.
5 citations
,
August 2025 in “Biomedicines” Early detection and multidisciplinary management of skin and mouth side effects from breast cancer treatments improve patient outcomes.
15 citations
,
January 2014 in “Medicinal chemistry” Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
53 citations
,
November 2014 in “International Journal of Oncology” Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.
4 citations
,
September 2010 in “Medical Hypotheses”
24 citations
,
November 2013 in “Trends in pharmacological sciences” Increasing ABC transporters in hair follicles may prevent chemotherapy-induced hair loss.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
7 citations
,
January 2016 in “Experimental and Clinical Endocrinology & Diabetes” Simvastatin may help manage symptoms in women with non-classic congenital adrenal hyperplasia by lowering cholesterol and certain hormone levels.
1 citations
,
June 2023 in “JAAD case reports” Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
3 citations
,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
1 citations
,
May 2012 in “Aktuelle Urologie” Chemoprevention, using drugs like finasteride and dutasteride, can help prevent prostate cancer.
15 citations
,
April 1997 in “Muscle & Nerve” 5 citations
,
April 1997 in “Muscle & Nerve” 105 citations
,
April 2014 in “Trends in Pharmacological Sciences” Targeting the Smoothened receptor shows promise for treating certain cancers.
September 2023 in “Journal of the American Academy of Dermatology” Methylprednisolone treatment helps most alopecia areata patients, but young age, extensive hair loss, and low vitamin D can affect results.
42 citations
,
January 2008 in “Clinical colorectal cancer” Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.
47 citations
,
July 2005 in “British Journal of Dermatology” Topical vitamin D3 does not prevent hair loss from chemotherapy.